Insulin Glargine Patient Assistance Program
Don’t let the high cost of brand or biosimilar long-acting basal insulin disrupt your diabetes treatment. We help eligible patients access insulin glargine (Lantus brand and biosimilars) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
Key Takeaways:
- Insulin glargine is FDA-approved as a long-acting basal insulin for treatment of diabetes in adults and pediatric patients. Available as brand Lantus (Sanofi) and multiple biosimilars/follow-on products: Basaglar (Lilly), Semglee (interchangeable biosimilar — Viatris), Rezvoglar (interchangeable biosimilar — Lilly), Toujeo (glargine U-300 — brand). ~24-hour duration for once-daily basal coverage. Foundation of basal-bolus insulin therapy for T1DM and many T2DM patients.
- Without assistance, brand Lantus costs approximately $300 per vial; biosimilars are significantly cheaper ($50–$150 per vial).
- Through AffordMyPrescriptions, qualifying patients can access insulin glargine for a flat $69.95 per month.
- Other long-acting basal insulins: Levemir (insulin detemir — brand; discontinued in US), Tresiba (insulin degludec — brand; ultra-long-acting ~42 hours). Rapid-acting bolus insulins: NovoLog (aspart), Fiasp, Merilog (aspart biosimilar), Humalog (lispro), Admelog (lispro biosimilar), Lyumjev, Apidra (glulisine). Under IRA, Medicare Part D insulin capped at $35/month. Voluntary manufacturer insulin caps ($35/month) for uninsured/underinsured. Walmart ReliOn cheap human insulin. American Diabetes Association resources.
What is Insulin Glargine Prescription Assistance Program?
The Insulin Glargine Patient Assistance Programs help eligible patients access this basal insulin at little or no cost when meeting income, insurance, and clinical criteria. The IRA Medicare Part D insulin cap ($35/month) and voluntary manufacturer insulin caps apply broadly.
At AffordMyPrescriptions, our Patient Advocates handle the entire enrollment for a flat $69.95 per month — so you never face a gap in your insulin glargine therapy.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your insulin glargine enrollment — so you never face a gap in your diabetes basal insulin therapy.
Pharmacy Price Comparison
- Insulin glargine biosimilars are significantly cheaper than brand Lantus. A Patient Assistance Program can offset costs if you qualify:
| PHARMACY | PRICE (30-DAY) WITH BEST COUPONS | YOU SAVE W/ US |
|---|---|---|
| Manufacturer $35 cap | $35/mo | Voluntary insulin cap |
| Walgreens (brand Lantus) | ~$300/vial | Save substantially |
| CVS Pharmacy (brand) | ~$300/vial | Save substantially |
| Walmart (biosimilar) | ~$80/vial | Save substantially |
| Costco (biosimilar) | ~$50/vial | Save substantially |
| IRA Medicare Part D cap | $35/mo | IRA Medicare cap |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Insulin Glargine — independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Insulin Glargine Prescription Program?
The Insulin Glargine Patient Assistance Program is free to apply. Our $69.95 per month covers full advocacy. The IRA Medicare Part D insulin cap ($35/month) is a major resource for Medicare beneficiaries. Voluntary manufacturer insulin caps ($35/month) are available for uninsured/underinsured. Biosimilars offer significant cost savings vs brand Lantus.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for Insulin Glargine assistance.
We Advocate
Our specialists gather documentation, complete applications, and coordinate with your prescriber and the assistance program.
Receive Medication
Once approved, your Insulin Glargine is delivered through the assistance program while we manage refills and annual renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Insulin Glargine:
Limitations of Coupons
Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
Coupon cards expire and require constant renewal
Still $50–$150 biosimilar / $300 brand per month even with the best discount
Cannot be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
Medicare Part D patients accepted
If denied, we explore alternative savings paths on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Insulin Glargine assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Insulin Glargine Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Insulin Glargine:
Insulin glargine is a long-acting basal insulin analog with ~24-hour duration — once-daily dosing for basal insulin coverage. Available as brand Lantus, follow-on Basaglar, and interchangeable biosimilars Semglee and Rezvoglar. The foundation of basal-bolus insulin therapy for diabetes.
How It Works:
Diabetes management involves matching insulin dosing to physiologic insulin needs. Basal insulin (long-acting) covers overnight and between-meal glucose control at ~50% of daily insulin needs; bolus insulin (rapid-acting) covers meals and corrections at ~50%. A basal-bolus regimen closely mimics physiologic insulin secretion. Long-acting analogs (glargine, detemir historically, degludec) provide a relatively flat 24-hour profile vs older NPH insulin. Insulin glargine is a modified human insulin with amino acid substitutions that shift its isoelectric point — causing microprecipitation at physiologic pH after SC injection and slowly dissolving to provide extended action ~24 hours. Once-daily dosing (though split BID may be needed for some patients). Multiple products: brand Lantus (Sanofi), follow-on Basaglar (Lilly), interchangeable biosimilars Semglee (Viatris) and Rezvoglar (Lilly), higher-concentration Toujeo (glargine U-300 — brand).
Form and Use:
Insulin glargine SC injection once daily (usually bedtime or morning) at a consistent time. Vials and pens available. Dose individualized based on fasting glucose targets and overall diabetes management. Diabetes education for proper insulin administration technique.
Generic Availability:
Multiple insulin glargine products with cost differences. Brand: Lantus (Sanofi). Follow-on/biosimilars (significantly cheaper): Basaglar (Lilly), Semglee (Viatris — interchangeable biosimilar), Rezvoglar (Lilly — interchangeable biosimilar). Higher-concentration: Toujeo (glargine U-300 — brand; flatter, longer profile). Other long-acting basal insulins: Tresiba (degludec — ultra-long-acting ~42 hours; brand). Rapid-acting insulins: NovoLog (aspart), Merilog (aspart biosimilar), Fiasp, Humalog (lispro), Admelog (lispro biosimilar), Lyumjev, Apidra (glulisine). Human insulin options (very cheap): NPH, Regular — Walmart ReliOn ~$25 per vial. IRA Medicare Part D insulin cap ($35/month). American Diabetes Association resources.
Warnings:
Hypoglycemia (the most common insulin adverse effect; educate patients on prevention and treatment; severe hypoglycemia can be fatal — glucagon rescue for severe episodes), hypokalemia (insulin drives potassium intracellularly), hypersensitivity reactions (rare — including anaphylaxis), lipodystrophy at injection sites (rotate sites), weight gain (chronic insulin therapy), embryo-fetal considerations (insulin is generally required in diabetic pregnancy — safe with careful glucose monitoring), fluid retention with concomitant thiazolidinediones. Other: injection site reactions. Continuous glucose monitoring or frequent testing is important. Diabetes education is essential.
FAQ (Frequently Asked Questions)
How much does insulin glargine cost without insurance?
Brand Lantus $300 per vial; biosimilars (Semglee, Rezvoglar, Basaglar) $50–$150 per vial — significantly cheaper. Under IRA Medicare Part D, insulin is capped at $35/month copay. Voluntary manufacturer insulin caps ($35/month) are available for many uninsured/underinsured.
What is the difference between Lantus and biosimilars?
Lantus is the brand (Sanofi). Follow-on/biosimilar products: Basaglar (Lilly), Semglee (Viatris — interchangeable biosimilar), Rezvoglar (Lilly — interchangeable biosimilar). All are insulin glargine with equivalent efficacy and safety. Interchangeable designation allows pharmacy substitution per state law, with significant cost savings.
How is Toujeo different from Lantus?
Both are insulin glargine. Toujeo is U-300 concentration (3x concentrated) vs Lantus U-100 — providing a flatter, longer-duration profile (~36 hours), particularly at higher doses. Brand only. May have less hypoglycemia risk in some patients. Individualized choice.
What insulin caps and programs help with cost?
IRA Medicare Part D insulin cap ($35/month copay for Medicare beneficiaries — 2023). Voluntary manufacturer insulin caps: Sanofi Lantus/Toujeo/Apidra ($35/month for uninsured/underinsured), Lilly Basaglar/Humalog ($35/month), Novo Nordisk NovoLog ($35/month). State insulin price caps in various states. Medicaid coverage.
What are insulin glargine side effects?
Hypoglycemia (most common — educate on prevention and treatment; use continuous glucose monitor or frequent testing), hypokalemia, hypersensitivity (rare), lipodystrophy at injection sites (rotate), weight gain, injection site reactions. Diabetes education is essential.
Take Control of Your Medication Costs
Affordable basal insulin is essential for diabetes management. Our advocacy team is ready — $69.95 per month, or free if we cannot help.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.